Biodesix director gets RSUs and stock options

Biodesix Inc. director and 10% owner Lawrence T. Kennedy Jr. reported awards of restricted stock units (RSUs) and stock options dated January 2, 2026.

Accepted by SEC EDGAR 01/06/2026 - 04:26 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Biodesix Inc. director and 10% owner Lawrence T. Kennedy Jr. reported awards of restricted stock units (RSUs) and stock options dated January 2, 2026. He received 5,443 RSUs, each representing a right to one share of common stock, which vest in four equal installments on March 31, June 30, September 30 and December 31, 2026, generally contingent on continued service and with no expiration date. These include deferred RSUs that will be settled in shares after his separation from service. He also received stock options for 6,354 shares at an exercise price of $6.46 per share, vesting on the same quarterly 2026 schedule and expiring on January 1, 2036.

Insider Trade Summary

Grant/Award: 11,797 shares

Grant/Award 2 txns

Insider Kennedy Lawrence T. Jr

Role Director, 10% Owner

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	5,443	$0.00	$0.00
Grant/Award	Stock Options (Right to Buy)	6,354	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 5,443 contracts (Direct); Stock Options (Right to Buy) — 6,354 contracts (Direct)

Footnotes (4)

1. F1. Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock ("Common Stock").
2. F2. These RSUs vest in four substantially equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.
3. F3. Represents deferred RSUs. The shares of Common Stock underlying these RSUs will be issued to the Reporting Person following the Reporting Person's separation from service with the Issuer.
4. F4. This option vests in four substantially equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to the Reporting Person's continued service with the Issuer.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Biodesix (BDSX) report for Lawrence T. Kennedy Jr.?

The report shows that Lawrence T. Kennedy Jr., a director and 10% owner of Biodesix (BDSX), received new restricted stock units and stock options on January 2, 2026.

How many RSUs were granted to the Biodesix (BDSX) insider on January 2, 2026?

Lawrence T. Kennedy Jr. was granted 5,443 restricted stock units (RSUs), each representing a right to receive one share of Biodesix common stock.

What is the vesting schedule for the Biodesix (BDSX) RSUs and options?

Both the 5,443 RSUs and the 6,354 stock options vest in four substantially equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to continued service.

What is the exercise price and expiration date of the Biodesix (BDSX) stock options?

The stock options granted to Lawrence T. Kennedy Jr. cover 6,354 shares of Biodesix common stock at an exercise price of $6.46 per share and expire on January 1, 2036.

How will the deferred RSUs for the Biodesix (BDSX) insider be settled?

The filing notes that certain RSUs are deferred, and the underlying shares of Biodesix common stock will be issued to Lawrence T. Kennedy Jr. following his separation from service with the company.

Does the Biodesix (BDSX) insider hold these awards directly or indirectly?

The Form 4 indicates the RSUs and stock options are held directly by Lawrence T. Kennedy Jr., with no indirect ownership entity listed for these specific grants.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kennedy Lawrence T. Jr

(Last) (First) (Middle)

1700 MADISON ROAD, SUITE 200

(Street)

CINCINNATI OH 45206

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIODESIX INC [ BDSX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	01/02/2026		A		5,443		(2)	(2)	Common Stock	5,443	$0	5,443(3)	D
Stock Options (Right to Buy)	$6.46	01/02/2026		A		6,354		(4)	01/01/2036	Common Stock	6,354	$0	6,354	D

Explanation of Responses:

1. Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock ("Common Stock").

2. These RSUs vest in four substantially equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

3. Represents deferred RSUs. The shares of Common Stock underlying these RSUs will be issued to the Reporting Person following the Reporting Person's separation from service with the Issuer.

4. This option vests in four substantially equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to the Reporting Person's continued service with the Issuer.

	/s/ Robin H. Cowie as Attorney-in-Fact for Lawrence T. Kennedy, Jr.	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.